Table 1.
Demographic details, clinical characteristics, visual acuity and visual field results of the treated eyes with stem cells and the untreated fellow eyes at baseline and at 1 year follow-up
| Subject No. | Age/sex/disease | Disease/study eye | BCVA baseline (logMAR) |
BCVA 1 year (logMAR) |
MD (dB) (Baseline) |
MD (dB) (1 year) |
|---|---|---|---|---|---|---|
| 1 | 19/F/SMD | OD (Fellow eye) | ＋0.60 | ＋0.70 | 15.5 | 23.7 |
| OS(Study eye) | ＋1.3 | ＋1.0 | 23.1 | 21.7 | ||
| 2 | 24/M/SMD | OD (Study eye) | ＋1.3 | ＋1.3 | 12.0 | 9.6 |
| OS(Fellow eye) | ＋1.3 | ＋1.6 | 13.3 | 14.7 | ||
| 3 | 20/M/SMD | OD (Study eye) | ＋2.0 | ＋1.5 | 28.1 | 28.6 |
| OS(Fellow eye) | ＋1.6 | ＋2.0 | 27.7 | 28.5 | ||
| 4 | 31/F/SMD | OD (Fellow eye) | ＋1.5 | ＋1.6 | 18.9 | 21.9 |
| OS(Study eye) | ＋1.5 | ＋1.0 | 21.6 | 19.1 | ||
| 5 | 75/M/AMD | OD (Fellow eye) | ＋1.0 | ＋1.3 | 6.5 | 10.6 |
| OS(Study eye) | ＋1.8 | ＋1.3 | 9.6 | 9.7 | ||
| 6 | 70/F/AMD | OD (Fellow eye) | ＋0.0 | ＋0.0 | 25.7 | 26.1 |
| OS(Study eye) | ＋2.0 | ＋1.3 | 24.5 | 20.2 | ||
| 7 | 60/M/AMD | OD (Study eye) | ＋1.8 | ＋1.3 | 6.4 | 6.2 |
| OS(Fellow eye) | ＋0.40 | ＋0.60 | 4.5 | 4.8 | ||
| 8 | 59/M/AMD | OD (Study eye) | ＋2.0 | ＋1.3 | 18.5 | 17.9 |
| OS(Fellow eye) | ＋0.70 | ＋1.0 | 7.3 | 8.6 |
AMD: Age related macular degeneration, BCVA: Best corrected visual acuity, logMAR: Logarithm of the minimum angle of resolution units OD: Oculus dexter, OS: Oculus sinister, SMD: Stargardts’ macular dystrophy, MD: Mean deviation dB: Decibel.
The numbers written in italics belong to the patients who experienced decrease during the follow-up period.